New laboratory perspectives for evaluation of vivax malaria infected patients: a useful tool for infection monitoring

• Autor(a) principal: Alves-Junior,Eduardo Rodrigues
• Data de Publicação: 2020
• Outros Autores: Gomes,Luciano Teixeira, Dombroski,Thaís Caroline Dallabona, Nery,Andréia Ferreira, Vandresen-Filho,Samuel, Nakazato,Luciano, Fontes,Cor Jesus Fernandes, Rios-Santos,Fabrício
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Infectious Diseases
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702020000200120
• topic: Plasmodium vivax; Laboratory biomarkers; Acute phase; Prognosis; Clinical status

ABSTRACT In recent years, the number of cases with severe Plasmodium vivax malaria has shown an increasing trend. It is, therefore, important to identify routine laboratory markers that best characterize the acute disease phase and can serve as a tool for clinical follow-up of patients. In a cohort study, we followed 87 patients with acute P. vivax monoinfection acquired in an endemic region of the Brazilian Amazon. Forty-two different biochemical and hematological parameters frequently tested in clinical routine were evaluated at the acute phase and the convalescent phase. A total of 42 laboratory tests were performed: biochemical parameters measured were serum lipids levels, aminotransferases, bilirubin, amylase, glucose, urea, creatinine, albumin, globulin, uric acid, C-reactive protein, and alpha-1-acid glycoprotein. Hematological parameters included total and differential white blood cell and platelet counts, hemoglobin concentration, mean platelet volume, platelet width distribution, and plateletcrit. Our results show that several biochemical and hematological parameters were associated with acute phase P. vivax malaria and these parameters reverted to normal values in the convalescent phase. The use of these parameters during diagnosis and follow-up of the infection is a useful clinical tool to evaluate the clinical course and therapeutic response of patients with uncomplicated vivax malaria.